Yamanouchi Vaprisol “approvable”
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Yamanouchi's Vaprisol (conivaptan) is "approvable" Nov. 30; FDA is requesting additional safety data for the hyponatremia agent. Discussions with the agency are ongoing but the company has not specified a timeframe for complete response. A September review by FDA's Endocrinologic & Metabolic Drugs Advisory Committee was cancelled. Vaprisol qualified for a priority review, but Yamanouchi opted for a standard review to allow time for the advisory committee to take place (1Pharmaceutical Approvals Monthly Nov. 1, 2004, p. 3)...
You may also be interested in...
FDA Has 19 Applications Remaining With User Fees In 2004: 7 NMEs, 1 BLA
With seven first-cycle new molecular entities with user fee deadlines in November and December, FDA could surpass the total number of new molecular entities approved in 2003.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.